Why Intellia’s lonvo-z Phase 3 data could raise expectations for one-time HAE treatment
Find out how Intellia’s lonvo-z Phase 3 data could change expectations for one-time hereditary angioedema treatment.
Pharma & Biotech
Pharma & Biotech
What Chiesi’s $1.9bn KalVista deal reveals about the next phase of rare disease consolidation
Rare disease M&A is shifting from science risk to launch execution. Chiesi’s KalVista deal puts oral HAE therapy at the center.
Pharma & Biotech
Will pediatric KONFIDENT-KID data accelerate KalVista’s sebetralstat approval in hereditary angioedema?
KalVista's sebetralstat pediatric trial data heads to Madrid. What it means for the HAE on-demand market and a 2026 FDA filing. Read the analysis.
Pharma & Biotech
FDA fast track for Argo Biopharma’s BW-20805 siRNA puts HAE’s next competitive battleground in focus
Argo Biopharmaceutical Co., Ltd. (Argo Biopharma), a Shanghai-based clinical-stage RNA interference therapeutics company, has received Fast Track Designation from the U.S. Food and Drug Administration for BW-20805, its investigational small interfering RNA therapy targeting prekallikrein for the prevention of hereditary angioedema attacks. The designation comes as the company runs a global Phase II open-label study
Pharma & Biotech
Why BioCryst’s Astria acquisition reshapes long-acting competition in hereditary angioedema prophylaxis
BioCryst completes its Astria acquisition to expand long-acting hereditary angioedema leadership. Find out what this means for HAE treatment competition.
Pharma & Biotech
Can KalVista’s refill-led EKTERLY growth signal a new standard in on-demand HAE care?
KalVista’s oral HAE drug EKTERLY hit $49M in 2025 sales. Discover what strong refill demand and global expansion mean for rare disease treatment models.